EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY

Month: April 2017

Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH

April 9, 2017

C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience

Read »

Enterprise Therapeutics Receives Funding from Cystic Fibrosis Trust

April 5, 2017

Brighton, UK, April 5, 2017 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of

Read »

Paul Sekhri Joins Topas Therapeutics as Chairman of the Board

April 4, 2017

Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election

Read »

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY

Month: April 2017

Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH

Enterprise Therapeutics Receives Funding from Cystic Fibrosis Trust

Paul Sekhri Joins Topas Therapeutics as Chairman of the Board

Categories

Archives